The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: MedMira

Monday Biotech Deal Review: February 13, 2012

Leave a Comment Posted by Jacob Cawker on February 13, 2012

Welcome to your Monday Biotech Deal Review for February 13, 2012. There was some interesting biotech activity over the previous two weeks, including the closing by Oncolytics of its $18.5M equity financing and the withdrawal by Valeant of its offer to acquire ISTA Pharmaceuticals and its acquisition of a Brazilian food and sport supplement company. [...]

Jacob Cawker, Monday Deal Review AbCelex Technologies, Andurja Beteiligungen, Bio-Methatech, Botaneco, CAN-med Healthcare, Cardinal Health, CardioComm Solutions, Carton Group, Demegen, Dinaco, Excelera Corporation, Futuremed Healthcare Products, Guided Therapeutics, Immunovaccine, Innovotech, ISTA Pharmaceuticals, MedMira, Oncolytics Biotech, Pacgen Biopharmaceuticals, Persistence Capital Partners, Probiotica Laboratorios, Pyng Medical, Syngenta, TZ Medical, Valeant Pharmaceuticals, Warnex

Monday Biotech Deal Review

Leave a Comment Posted by Jacob Cawker on July 18, 2011

Welcome to your Monday Biotech Deal Review for July 18, 2011. Of note over the past week was the completion of Trimel’s qualifying transaction under the TSX-V’s capital pool company regime, resulting in Trimel’s expected re-listing on the TSX. Also noteworthy was Valeant’s buying spree in the dermatology sector, with the purchase of dermatology assets [...]

Jacob Cawker, Monday Deal Review Centre for Drug Research and Development, Inc., Innovotech, J5 (Barbados), Janssen Pharmaceuticals, Kolmi-Hopen Group, Labopharm, Ltd., Medicom(R), MedMira, Microbix Biosystems, Northern Securities Inc., PharmaGap, Sanofi, SC Stormont Holdings, TEC Edmonton, Trimel BioPharma Holdings Inc., Trimel Pharmaceuticals Corporation, Triplex International Biosciences Co., Valeant Pharmaceuticals International

Monday Biotech Deal Review: April 18, 2011

Leave a Comment Posted by Jacob Cawker on April 18, 2011

Welcome to your Monday Biotech Deal Review for April 18, 2011. Just by way of FYI, readers may be interested to know that The Canadian Institute will be hosting its 5th annual conference on Drug Pricing and Reimbursement in Canada in Toronto from June 14 – 15 at the Sutton Place Hotel. The conference aims [...]

Jacob Cawker, Monday Deal Review Applied Biology Company, Arch Biopartners, Atrium Innovations, BC Cancer Agency, BioSyent, CardioComm Solutions, Centre for Drug Research and Development, Champions Oncology, Chemophor, CIT Safety & Health Research Company, Compass Biotechnologies, Critical Outcome Technologies, Dutchess Opportunity Cayman Fund Limited, Equity Communications Ontario, Glenveigh International, Hemispherx Biopharma, iCo Therapeutics, Immunovaccine, Kane Biotech, LAB Research, LLC, MedMira, Ondine Biomedical, PanGen Biotech, Quest PharmaTech, Robert & Fils, SQI Diagnostics, Thallion Pharmaceuticals, The Canadian Institute, Theramed Corporation, University of North Carolina Kidney Center

Monday Biotech Deal Review: April 11, 2011

1 Comment Posted by Jacob Cawker on April 11, 2011

Welcome to your Monday Biotech Deal Review for April 11, 2011. Notable events in the Canadian biotech space over the past week included: (i) the filing by Valeant with the SEC of a consent solicitation statement in furtherance of its efforts to replace the board of its hostile target Cephalon; (ii) the approval by creditors [...]

Jacob Cawker, Monday Deal Review A.R.E. Quebec No. 2, Abraxis Bioscience, Agahan Ayandeye Pars, AlCana Technologies, ALDA Pharmaceuticals, Alnylam Pharmaceuticals, Altius Edge, Ambrilia Biopharma, Angiotech Pharmaceuticals, BELLUS Health, Bradmer Pharmaceuticals, Cangene Corporation, Cephalon, Critical Outcome Technologies, HEI, Immunall Science, Inc., Kane Biotech, Meda Pharmaceuticals, Medicago, MedMira, MethylGene, Miraculins, Mosaic Limited Partnership, MTS Securities, P1 Energy Corp, Pacgen Biopharmaceuticals, Pharmagesic (Holdings), ProMetic Life Sciences, The University of British Columbia, Triplex International Biosciences Co., Valeant Pharmaceuticals International, WEX Pharmaceuticals

Monday Biotech Deal Review: December 6, 2010

1 Comment Posted by Jacob Cawker on December 6, 2010

Welcome to your Monday Biotech Deal Review. There was some activity with Angiotech last week, with extension agreements being executed extending certain deadlines dealing with Angiotech’s proposed recapitalization as well as a preliminary loss in court against Rex Medical L.P. Read on to learn more, as well as your usual assortment of biotech news.

Jacob Cawker, Monday Deal Review A5 Laboratories, Allon Therapeutics, Angiotech Pharmaceuticals, Bioniche Life Sciences, CreoSalus, Crucible International Biotechnologies, Cynapsus Therapeutics, Dartmouth-Hitchcock Medical Center, Functional Technologies, Hologic, Immunovaccine, IMRIS, IntelGenx, Lorus THerapeutics, MedMira, Michael J. Fox Foundation, Microbix Biosystems, OncoTherapy Science, Paladin Labs, Patheon, Rex Medical L.P., Thallion Pharmaceuticals, Theralase Technologies, Theratechnologies, Thorn BioScience

Monday Biotech Deal Review: October 4, 2010

5 Comments Posted by Jacob Cawker on October 4, 2010

This week’s Monday Deal Review brings you the usual assortment of biotech wheelings and dealings from the past week, including a summary of the newly completed Valeant / Biovail merger.

Jacob Cawker, Monday Deal Review Ambrilia Biopharma, Angiotech, Bioniche, Biovail, Kane Biotech, Leap Medical, Lorus THerapeutics, MedMira, NeurAxon, Northstar Healthcare, Ondine Biopharma, Pulmokine, SemBioSys Genetics Inc., Stellar Biotechnologies, Valeant, YM Biosciences

Monday Biotech Deal Review: July 12, 2010

1 Comment Posted by Jeremy Grushcow on July 12, 2010

This week saw several interesting deals, including an $85+ million exit for Sentinelle, some “bio-bucks” made good for Cipher, a licensing deal for Amorfix’s vCJD technology, a $10 million malaria deal for BC-based Artepharm and a new name (Medwell Capital) to go along with BioMS’ new business model.

Jeremy Grushcow, Monday Deal Review AECL, Amorfix, Angiotech, Artepharm, BioMS, Bradmer Pharmaceuticals, Canada Economic Development, Chemaphor, Cipher Pharmaceuticals, GDG Environment Group, Hercules Technology Growth Capital, Hologic, Kowa Pharmaceuticals America, Labopharm, Lantheus Medical Imaging, MDS Nordion, MedMira, Medwell Capital, Medworxx, Merck, Merus Labs, Methapharm, Miraculins, NRC, Ondine Biopharma, Osta Biotechnologies, Paradigm Capital, PharmaTrust, Qater, reMYND, Sentinelle, Silicon Valley Bank, Sinuwave Technologies, T-Ray Science, Teraview, Titan Medical, Urodynamix Technologies

Monday Biotech Deal Review: June 21, 2010

1 Comment Posted by Jeremy Grushcow on June 21, 2010

This week saw a slew of licensing and commercial deals, including HIV programs for MedMira in Nigeria and Dignitas in Malawi. On the securities side, Aquinox’s $25 million B round headlined a $47 million week. Rounding out the week is Enerkem’s demonstration project funding, which will go towards reducing emissions from biorefineries.

Jeremy Grushcow, Monday Deal Review Aeterna Zentaris, Aquinox Pharmaceuticals, Beverage Supply Group, C.R. Bard Inc., Climate Change and Emissions Management Corporation, Covalon Technologies, Creare, Dignitas International, Enerkem, Functional Technologies, Medicago, MedMira, Resverlogix, Sonomax Technologies, SQI Diagnostics

Monday Biotech Deal Review: May 31, 2010

1 Comment Posted by Jeremy Grushcow on May 31, 2010

Things are picking up a bit this week, with a few new financings, some collaboration agreements and a deal in the venture capital community that coincided with the CVCA’s annual meeting.

Jeremy Grushcow, Monday Deal Review ALDA Pharmaceuticals Corp., Amorfix, Aragen Bioscience, Cangene, CardioComm Solutions, Critical Outcome Technologies, GrowthWorks, iCo Therapeutics, Isis Pharmaceuticals, Lorus THerapeutics, MedMira, Pacgen Biopharmaceuticals, Resverlogix, Roseway Capital

Monday Biotech Deal Review: April 26, 2010

1 Comment Posted by Jeremy Grushcow on April 26, 2010

This week’s deals are highlighted by a new TSX-V listed biotech, a $16 million D round, five collaborations a FedDev win for Bioniche, and updates on this month’s flurry of financings.

Jeremy Grushcow, Monday Deal Review Aeterna Zentaris, Axela, Baxter Healthcare, Bioniche, Biosign Technologies, Cangene, CPC, DiaMedica, Gemin X Pharmaceuticals, ImmunoVaccine Technologies, IntelGenx Technologies, MedMira, Nightingale Informatix Corporation, Pacgen Biopharmaceuticals, Stellar Biotechnologies

Monday Biotech Deal Review: November 16, 2009

2 Comments Posted by Jeremy Grushcow on November 16, 2009

This week’s Canadian biotech roundup features a dose of all kinds of deals, though common shares appear to be figuring more prominently lately than they were earlier in 2009. Lots of multijurisdictional activity too, with the U.S., the UK and Germany all participating in this week’s transactions. Other notable cross-border developments include the acquisition of [...]

Jeremy Grushcow, Monday Deal Review Andurja, Cangene, Dimethaid, Immunovaccine, Medicago, MedMira, NUCRYST, Nuvo Research, Prism Medical, Ranbaxy, Smith & Nephew, SQI Diagnostics, Vitest, Westaim

Monday Biotech Deal Review: October 12, 2009

1 Comment Posted by Jeremy Grushcow on October 12, 2009

Here’s the roundup for today. It’s the Canadian Thanksgiving weekend, but there’s not a turkey in the bunch.

Jeremy Grushcow, Monday Deal Review Biosign Technologies, CML Healthcare, J.F. Mackie, MDS Analytical Technologies, MDS Inc., Medicago, MedMira, Noveko International, Sonomax Hearing Healthcare, Stem Cell Therapeutics

Monday Biotech Deal Review: September 14, 2009

4 Comments Posted by Jeremy Grushcow on September 14, 2009

The Monday Deal Review is back in full force this week following a Labo(u)r Day vacation last week and there’s plenty of news including more information on the MDS-Danaher transaction and plenty of other companies finding ways to raise money and keep the lights on. Keep reading

Jeremy Grushcow, Monday Deal Review Akela Pharma, BELLUS Health, BioSyntech, Bradmer Pharmaceuticals, Cannasat Therapeutics, Cardiome Pharma, Danaher, Development Bank of Saxony, Fraunhofer Institute for Cell Therapy, Helix BioPharma, Life Technologies, MDS Inc., Medicure Inc., MedMira, MethylGene Inc., Microbix Biosystems, Noveko International, Nuvo Research, Urodynamix Technologies

Monday Deal Review: August 24, 2009

1 Comment Posted by Jeremy Grushcow on August 24, 2009

This week saw a few headline deals that we covered at the time, including the Vasogen-Cervus-IntelliPharmaCeutics deal, the move by Takeda Canada to take back ACTOS rights from Lilly, and the Lonza offer for Patheon, but other than that it seems like it was a quiet week everywhere. Still, check out some good stuff

Jeremy Grushcow, Monday Deal Review Ajanta Pharma, Angiotech, Cervus, Colabor Income Fund, ConjuChem, Eli Lilly, IntelliPharmaCeutics, JLL Partners, Lonza, Medicago, MedMira, Patheon, Rex Medical, Takeda Canada, Vasogen

Monday Deal Review: August 17, 2009

3 Comments Posted by Jeremy Grushcow on August 17, 2009

In addition to the highlights already noted — Enobia’s $50 million r0und, and the LOM – BioQuest joint venture — there was plenty of other Canadian deal activity this week. Check it out

Jeremy Grushcow, Monday Deal Review BioQuest, BioSyntech, Clinical Data Inc., Colabor Income Fund, CombinatoRx, ConjuChem, Enobia, GeneNews, IMBiotechnologies, Jennerex, JLL Partners, LAB Research Inc., LOM, Medicure Inc., MedMira, Neuromed, Oncothyreon, Pacgen Biopharmaceuticals, Paladin Labs, Patheon, Prism Medical, Pyng Medical, Rosetta Genomics, Warex Medical Laboratories, Xphase Pharmaceuticals

Monday Deal Review: August 10, 2009

3 Comments Posted by Jeremy Grushcow on August 10, 2009

Considering last week was abbreviated for the August long weekend here in Canada, there’s a decent amount of activity to run through. Check out this week’s deals

Jeremy Grushcow, Monday Deal Review Cannasat Therapeutics, Chemaphor, EDC, Elanco, Eli Lilly, Export Development Canada, Investissement Quebec, LAB Research Inc., Labopharm, MedMira, Nightingale Informatix Corporation, Oncogenex, Sandfire Securities, Solidarity Fund QFL, Wellington Financial

Monday Deal Review: July 27, 2009

1 Comment Posted by Jeremy Grushcow on July 27, 2009

Well, July is wrapping up with no sign of summer, or of the summer doldrums. Read on for all the rainy-day deals we found this week

Jeremy Grushcow, Monday Deal Review Ambrilia Biopharma, Angiotech, Bioniche, CQDM, DiagnoCure, Genopole biopark, ImmunoVaccine Technologies, LMS Medical Systems, Medicago, MedMira, NRC-IRAP, Oncogenex, SemBioSys Genetics Inc., VWR Scientific

Monday Deal Review: July 6, 2009

5 Comments Posted by Jeremy Grushcow on July 6, 2009

Learn more about Neuromed’s deal with CombinatoRx, check out what MedMira’s been doing with all the cash from its equity line, and find out who’s closed deals and who’s just closing doors in this week’s Monday Deal Review

Jeremy Grushcow, Monday Deal Review Adaltis, Akela Pharma, CombinatoRx, MDS Inc., MedMira, Neuromed, Oncoscience AG, Tekes, Triplex International Biosciences, YM Biosciences

Monday Deal Review: June 22, 2009

5 Comments Posted by Jeremy Grushcow on June 22, 2009

A whole gaggle of securities deals, a cluster of licenses and a flock of M&A all migrate back to Canada for summer in this week’s Monday Deal Review. Plus, a deal that may improve the medical isotope shortage.

Jeremy Grushcow, Monday Deal Review Aeterna Zentaris, Akela Pharma, ALERT B&C, Amorfix, Covidien, Isotechnika, JLL Partners, Karpov Institute of Physical Chemistry, Mallinckrodt, MDS Nordion, MedMira, Neuromed, Nuvo Research, Nventa Biopharmaceuticals, Otto Bock, Paladin Labs, Patheon, PharmaGap, SemBioSys Genetics Inc., Teikoku Seiyaku, Victhom Human Bionics

Monday Deal Review: June 15, 2009

1 Comment Posted by Jeremy Grushcow on June 15, 2009

Another active week for Canadian deals, headed by Merck’s new deal with Xenon, along with some new funding, some new collaborations, and some new products coming to, and going from, Canadian companies all for your easy-reading pleasure

Jeremy Grushcow, Monday Deal Review Advitech, Aeterna Zentaris, Ardana Biosciences, Canadian Hospital Specialties, Caprion Proteomics, CQDM, Havel's, Jennerex, Medicago, Medifocus, MedMira, OICR, Ottawa Health Research Institute, Quebec Consortium for Drug Discovery, SQI Diagnostics

Monday Deal Review: June 8, 2009

4 Comments Posted by Jeremy Grushcow on June 9, 2009

Well, it’s a day late, but no dollars short. Here is an action-packed Deal Review. Read on for some debt settlement, some creditor un-settlment (a BIA filing), and all kinds of M&A related rejigging…

Jeremy Grushcow, Monday Deal Review Atwell Capital, AVENTIX Animal Health, Baylis Medical Company, debt settlement, Eklin Medical Systems, Fralex Therapeutics, JLL Partners, LMS Medical Systems, MDS Inc., MDS Pharma Services, MedMira, Patheon, Theratechnologies, Vineland Research and Innovation Centre

Monday Deal Review: June 1, 2009

1 Comment Posted by Jeremy Grushcow on June 1, 2009

Looks like most people were too busy at ASCO to make new deals, but there was a bit of Canadian activity this week. Read on

Jeremy Grushcow, Monday Deal Review MedMira, Oncothyreon

Monday Deal Review: May 11, 2009

5 Comments Posted by Jeremy Grushcow on May 11, 2009

Check out the latest Patheon-JLL developments, a licensing deal that looks like a subcontracting arrangement, a plan of arrangement M&A that looks like a license, and the rest of the Canadian deal info from this past week

Jeremy Grushcow, Monday Deal Review Angiotech, AVAC, Cangene, Haemacure, Isotechnika, JLL Partners, Maxygen, MedMira, Paladin Labs, Patheon, Response Biomedical, Roche, SemBioSys Genetics Inc., voclosporin

Monday Deal Review: April 27, 2009

2 Comments Posted by Jeremy Grushcow on April 27, 2009

Biotech deal activity in Canada was back on the upswing a bit this week, with some private placements, issuer bids, and an equity line of credit…

Jeremy Grushcow, Monday Deal Review Amorfix, BioMosaics, equity line of credit, JLL Partners, MedMira, Neovasc, OICR, Patheon, private placement, Sunnybrook Research Institute

Monday Deal Review: March 16, 2009

3 Comments Posted by Jeremy Grushcow on March 16, 2009

M&A: We already noted the JLL bid for Patheon this week, and the Patheon Special Committee’s response. It turns out that JLL has been a busy enterprise lately, extending the expiration on a bid for PharmaNet Development Group, Inc. (Nasdaq: PDGI). Partnering: MedMira Inc., (TSX-V:MIR, NASDAQ: MMIRF), which has been active on the securities front with a [...]

Jeremy Grushcow, Monday Deal Review Advitech, AgeChem, Akela Pharma, Caisse de Depot, Cytognomix, delisting review, Helix BioPharma, HIV Test, JLL Partners, LAB Research Inc., litigation settlement, LMS Medical Systems, MedMira, Michael Sabia, Ontario Genomics Institute, Patheon, PharmaNet, Pre-commercialization Business Development Fund, private placement, Resverlogix, Spectral Diagnostics, Toray Industries, Vitest

Monday Deal Review: March 2, 2009

1 Comment Posted by Jeremy Grushcow on March 2, 2009

Canadian deals and company info from this week

Jeremy Grushcow, Monday Deal Review ALERT B&C, Angiotech, Canadian Breast Cancer Foundation, CMDF, debt settlement, GrowthWorks, MedMira, merger, PharmaGap, PreMD, private placement, SC Stormont, Victhom Human Bionics

Monday Deal Review: February 9, 2009

3 Comments Posted by Jeremy Grushcow on February 9, 2009

Jeremy Grushcow, Monday Deal Review MedMira, Medworxx, Morningside Asia, Vasogen

RSS feed

The views expressed here are solely the authors’ and should not be attributed to any of their firms or clients. The material and information provided on this website are for general information only and should not be relied on as legal or business advice or as a legal opinion. The authors make no claims, promises or guarantees about the accuracy, completeness, currency, or adequacy of any information linked or referred to or contained on this blog. No person should act or refrain from acting in reliance on any information found on this blog without first obtaining appropriate professional advice from a consultant or from a lawyer duly licensed to practise law in the relevant province, state, territory or country. These materials do not create a solicitor-client relationship between you and any author. Please note that the authors will not provide free legal, financial or other advice. Please don’t send us any confidential information or questions by email or otherwise because any information sent to us cannot be considered to be privileged or confidential. Note that by accessing, commenting on or linking to the blog, you (like us) are subject to the WordPress Terms of Service. Most images are from Wikimedia Commons or from governments, others link back to commercial sources. If you want us to remove an image, just let us know.